Literature DB >> 15777507

[Apoptosis-related gene expression and its clinical significance of human osteosarcoma].

Xing Wu1, Zheng-rong Chen, Guang-jian Zhang.   

Abstract

OBJECTIVE: To explore the prognostic markers in osteosarcoma.
METHODS: Expressions of p53, c-myc, bcl-2 and apoptosis index (AI) in 28 osteosarcoma specimens were detected by ABC immunohistochemistry and terminal deoxynucleotidyl transferase (TdT)-mediated dUTP-digoxigenin nick end labelling (TUNEL). The relationship between gene expression and apoptosis, and their correlations with pathologic classification and prognostic factors were analyzed.
RESULTS: There was negative correlation between the expressions of p53, c-myc, bcl-2 protein and AI, which was closely related to the long term survival of patients but was not related to pathologic types of the tumor.
CONCLUSION: The expressions of p53, c-myc, bcl-2 protein and AI can be used as an index for predicting the progression and prognosis of osteosarcoma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15777507

Source DB:  PubMed          Journal:  Zhonghua Zhong Liu Za Zhi        ISSN: 0253-3766


  4 in total

1.  Comment on Fu et al.: A systematic review of p53 as a biomarker of survival in patients with osteosarcoma.

Authors:  Jinjun Chen; Lanlan Ma; Guanghui Wei
Journal:  Tumour Biol       Date:  2013-12-22

Review 2.  A systematic review of p53 as a biomarker of survival in patients with osteosarcoma.

Authors:  Hai-Liang Fu; Lin Shao; Qiang Wang; Tao Jia; Ming Li; Da-Ping Yang
Journal:  Tumour Biol       Date:  2013-09-07

3.  Antitumor activity of natural compounds, curcumin and PKF118-310, as Wnt/β-catenin antagonists against human osteosarcoma cells.

Authors:  Pay-Chin Leow; Quan Tian; Zhan-Yuin Ong; Zheng Yang; Pui-Lai Rachel Ee
Journal:  Invest New Drugs       Date:  2010-12       Impact factor: 3.850

4.  Identifying biomolecules and constructing a prognostic risk prediction model for recurrence in osteosarcoma.

Authors:  Minglei Zhang; Yang Liu; Daliang Kong
Journal:  J Bone Oncol       Date:  2020-10-21       Impact factor: 4.072

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.